FDA approves topical corticosteroid for treatment of dry eye disease
October 27, 2020
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% for short-term treatment of the signs and symptoms of dry eye disease.
April 07, 2021
Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery.
October 27, 2020
The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% for short-term treatment of the signs and symptoms of dry eye disease.
August 06, 2020
This action will result in 2 separate companies,